Number of the records: 1
Aurora kinase inhibitors: Progress towards the clinic
- 1.
SYSNO ASEP 0377543 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title Aurora kinase inhibitors: Progress towards the clinic Author(s) Kollareddy, M. (CZ)
Zheleva, D. (GB)
Dzubak, P. (CZ)
Brahmkshatriya, Pathik (UOCHB-X)
Lepšík, Martin (UOCHB-X) RID, ORCID
Hajduch, M. (CZ)Number of authors 6 Source Title Investigational New Drugs. - : Springer - ISSN 0167-6997
Roč. 30, č. 6 (2012), s. 2411-2432Number of pages 22 s. Language eng - English Country US - United States Keywords Aurora kinases ; cancer ; inhibitors Subject RIV CF - Physical ; Theoretical Chemistry CEZ AV0Z40550506 - UOCHB-X (2005-2011) UT WOS 000310470100036 DOI 10.1007/s10637-012-9798-6 Annotation The Aurora kinases (serine/threonine kinases) were discovered in 1995 during studies of mutant alleles associated with abnormal spindle pole formation in Drosophila melanogaster. They soon became the focus of much attention because of their importance in human biology and association with cancer. Aurora kinases are essential for cell division and are primarily active during mitosis. Following their identification as potential targets for cancer chemotherapy, many Aurora kinase inhibitors have been discovered and developed. Currently, there are about 30 Aurora kinase inhibitors in different stages of pre-clinical and clinical development. This review summarizes the characteristics and status of Aurora kinase inhibitors in preclinical, Phase I, and Phase II clinical studies, with particular emphasis on the mechanisms of action and resistance to these promising anticancer agents. Workplace Institute of Organic Chemistry and Biochemistry Contact asep@uochb.cas.cz ; Kateřina Šperková, Tel.: 232 002 584 ; Viktorie Chládková, Tel.: 232 002 434 Year of Publishing 2013
Number of the records: 1